» Articles » PMID: 32341228

Prevalence of Biopsy-proven Nonalcoholic Fatty Liver Among Patients with Gallstone Disease

Abstract

Background/aim: Gallstone disease (GD) and nonalcoholic fatty liver disease (NAFLD) are associated with metabolic syndrome. Despite the benign nature of NAFLD, 10% of patients may develop advanced fibrosis and cirrhosis. We aimed to identify the prevalence and factors associated with NAFLD among GD patients in the Saudi population.

Patients And Methods: This is a single-center, observational cohort study that included patients seen in general surgery clinics at our institution from 2011 to 2017. All liver biopsies were taken at the same time as the cholecystectomy. Demographical and clinical data were prospectively collected from the study population.

Results: Of the 301 GD patients in the study, 15% had a normal body mass index (BMI), 29% were overweight, and 56% were obese. There were 143 (47.8%) patients with NAFLD, of which 125 (41.8%) showed steatosis and 18 (6%) had nonalcoholic steatohepatitis. There was a significant positive correlation between NAFLD and age (r = 0.243; P < 0.0001), and BMI (r = 0.242; P < 0.0001). Obese patients with BMI 30-40 kg/m were 2.403 (P = 0.039) more likely to have NAFLD compared with normal BMI patients, and this value increased to 6.145 (P = 0.002) in patients with BMI >40 kg/m. Additionally, patients with T2DM were 2.839 times (P = 0.015) more likely to have NAFLD compared with those who did not.

Conclusions: The prevalence of NAFLD among GD patients is high. High BMI and diabetes are independent factors associated with NAFLD in GD patients. The results suggest that there may be a need for routine liver biopsy in selected patients during cholecystectomy.

Citing Articles

Liver biopsy in patients with gall stone disease and concomitant non-alcoholic fatty liver disease undergoing cholecystectomy: A prospective observational study.

John A, Anand U, Kumar T, Kodali R, Parasar K, Kumar R Turk J Surg. 2025; 40(3):190-196.

PMID: 39917405 PMC: 11792899. DOI: 10.47717/turkjsurg.2024.6488.


Non-alcoholic Fatty Liver Disease and Gallstones: A Systematic Review.

Slouha E, Biput S, Kuteyi A, Kalloo A, Gorantla V Cureus. 2023; 15(9):e45027.

PMID: 37829934 PMC: 10566311. DOI: 10.7759/cureus.45027.


Management of nonalcoholic fatty liver disease in the Middle East.

Sanai F, Abaalkhail F, Hasan F, Farooqi M, Nahdi N, Younossi Z World J Gastroenterol. 2020; 26(25):3528-3541.

PMID: 32742124 PMC: 7366060. DOI: 10.3748/wjg.v26.i25.3528.

References
1.
Ramos-De la Medina A, Remes-Troche J, Roesch-Dietlen F, Perez-Morales A, Martinez S, Cid-Juarez S . Routine liver biopsy to screen for nonalcoholic fatty liver disease (NAFLD) during cholecystectomy for gallstone disease: is it justified?. J Gastrointest Surg. 2008; 12(12):2097-102. DOI: 10.1007/s11605-008-0704-7. View

2.
Sanyal A . AGA technical review on nonalcoholic fatty liver disease. Gastroenterology. 2002; 123(5):1705-25. DOI: 10.1053/gast.2002.36572. View

3.
Garcia-Monzon C, Vargas-Castrillon J, Porrero J, Alonso M, Bonachia O, Castillo M . Prevalence and risk factors for biopsy-proven non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in a prospective cohort of adult patients with gallstones. Liver Int. 2015; 35(8):1983-91. DOI: 10.1111/liv.12813. View

4.
Mikolasevic I, Orlic L, Franjic N, Hauser G, Stimac D, Milic S . Transient elastography (FibroScan(®)) with controlled attenuation parameter in the assessment of liver steatosis and fibrosis in patients with nonalcoholic fatty liver disease - Where do we stand?. World J Gastroenterol. 2016; 22(32):7236-51. PMC: 4997649. DOI: 10.3748/wjg.v22.i32.7236. View

5.
Spengler E, Loomba R . Recommendations for Diagnosis, Referral for Liver Biopsy, and Treatment of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis. Mayo Clin Proc. 2015; 90(9):1233-46. PMC: 4567478. DOI: 10.1016/j.mayocp.2015.06.013. View